What is Delcath Systems's market cap?

Delcath Systems (DCTH) has a market capitalization of $412.2M and trades on NASDAQ.

What is Delcath Systems's revenue and profitability?

Delcath Systems generated $90.4M in trailing twelve-month revenue with net income of $3.5M, representing a net margin of 1.5%. Gross margin stands at 86.0%, with free cash flow of $19.2M. These figures are based on the Q1 2026 filing.

Who are Delcath Systems's competitors?

Delcath Systems's key competitors include Boston Scientific, Merit Medical Systems, Citius Oncology, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Where is Delcath Systems headquartered?

Delcath Systems is headquartered in United States of America and employs approximately 76 people. It has been publicly traded since 2000.

Delcath Systems

DCTH

Delcath Systems is an interventional oncology company specializing in the treatment of primary and metastatic liver cancers.

Market cap

$412.19M+8.3%

Revenue$90.4M+68.0%

Net income$3.5M+113%

Free cash flow$19.2M+353%

EPS (diluted)$0.09+109%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$25.0MBeat by $1.5M EPS-$0.03Beat by $0.06

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$26.3M

EPS estimate-$0.09

Financials

Q1 2026

Income statement

See full

Revenue$25.0M+26.3%

Gross profit$21.3M+25.5%

Operating income-$1.6M-355%

Net income-$1.1M-200%

EPS (diluted)-$0.03-200%

Balance sheet

See full

Cash & equivalents$41.3M+223%

Total debt$907.0K-10.7%

Total equity$112.7M+40.5%

Total assets$124.8M+43.0%

Cash flow

See full

Operating cash flow$857.0K-61.1%

CapEx$570.0K+307%

Free cash flow$287.0K-86.1%

Valuation & ratios

Valuation

See full

Market cap$412.19M+8.3%

Enterprise value$371.8M+2.2%

P/E116.9×—

P/S4.6×-1.1×

Profitability

See full

Gross margin86%+1.1pp

FCF margin21.2%+15.2pp

Returns & leverage

See full

Debt / equity0×0.0×

Current ratio11.2×-4.7×

Segments

By product

See full

HEPZATO KIT$23.2M+29.0%

CHEMOSAT$1.7M-0.8%

By geography

See full

Foreign$1.7M-0.8%

Competitors

By market cap

Boston Scientific$67.6B-56.8%

Mirum Pharmaceuticals, Inc.$7.0B+173%

Merit Medical Systems$4.5B-9.1%

Altimmune$575.6M+76.1%

Delcath Systems$412.2M+3.7%

TriSalus Life Sciences, Inc.$265.3M+53.6%

ADC Therapeutics$145.0M-58.6%

CTO

Citius Oncology, Inc.$51.7M-64.7%

By revenue growth

Delcath Systems+68.0%

Mirum Pharmaceuticals, Inc.+50.2%

TriSalus Life Sciences, Inc.+39.6%

Boston Scientific+17.4%

Merit Medical Systems+11.1%

By net margin

Boston Scientific17.26%+5.7pp

Merit Medical Systems9.03%+0.2pp

Delcath Systems1.51%+52.9pp

TriSalus Life Sciences, Inc.-60.85%+23.8pp

Mirum Pharmaceuticals, Inc.-140.24%-120pp

Altimmune-214,860.98%—

Profile

Delcath Systems is an interventional oncology company specializing in the treatment of primary and metastatic liver cancers. The company's core value proposition is its proprietary drug/device combination system designed to deliver high-dose chemotherapy directly to the liver while minimizing systemic exposure. Its lead technology platform enables targeted treatment for patients with unresectable hepatic metastases, particularly those originating from uveal melanoma.

Competitive position

A specialized player in the liver-directed therapy market with FDA-approved orphan drug designations for its lead combination product.

GeographiesUnited States, Europe

Customer segmentsSpecialized Healthcare Providers, Tertiary Care Centers

Business modelProduct Manufacturing, Direct Sales

SuppliersPharmaceutical ingredient manufacturers, Medical device component suppliers, Contract manufacturers

CustomersOncology departments, Specialty hospitals, Medical distributors

CountryUnited States of America

Listed2000

Employees76.0

CEOGerard J. Michel

SectorHealthcare

IndustryMedical - Specialties

Websitedelcath.com

FilingsSEC EDGAR

Ask your AI about Delcath Systems.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Delcath Systems's market cap?: Delcath Systems (DCTH) has a market capitalization of $412.2M and trades on NASDAQ.
What is Delcath Systems's revenue and profitability?: Delcath Systems generated $90.4M in trailing twelve-month revenue with net income of $3.5M, representing a net margin of 1.5%. Gross margin stands at 86.0%, with free cash flow of $19.2M. These figures are based on the Q1 2026 filing.
Who are Delcath Systems's competitors?: Delcath Systems's key competitors include Boston Scientific, Merit Medical Systems, Citius Oncology, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Where is Delcath Systems headquartered?: Delcath Systems is headquartered in United States of America and employs approximately 76 people. It has been publicly traded since 2000.